Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.

Geusens PP, Truitt K, Sfikakis P, Zhao PL, DeTora L, Shingo S, Lau CS, Kalla A, Tate G.

Scand J Rheumatol. 2002;31(4):230-8.

PMID:
12369656
3.

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.

Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW.

Clin Ther. 1999 Oct;21(10):1688-702.

PMID:
10566565
4.

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.

Myllykangas-Luosujärvi R, Lu HS, Chen SL, Choon D, Amante C, Chow CT, Pasero G, Genti G, Sarembock B, Zerbini CA, Vrijens F, Moan A, Rodgers DB, De Tora L, Laurenzi M; Naproxen 901 OF study group Naproxen 901 OC study group.

Scand J Rheumatol. 2002;31(6):337-44.

PMID:
12492248
6.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S; Etoricoxib Rheumatoid Arthritis Study Group.

J Rheumatol. 2002 Aug;29(8):1623-30.

PMID:
12180720
7.

Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.

Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE 2nd, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O.

Clin Ther. 2006 Sep;28(9):1279-95.

PMID:
17062301
8.

A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.

Williams GW, Kivitz AJ, Brown MT, Verburg KM.

Clin Ther. 2006 Feb;28(2):204-21.

PMID:
16678642
10.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
11.

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.

J Rheumatol. 1999 Nov;26(11):2438-47.

PMID:
10555907
12.
13.

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial.

Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B.

Clin Ther. 1999 Jun;21(6):943-53.

PMID:
10440619
14.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
15.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
16.

Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.

Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D; Vioxx Chronic Low Back Pain Study Group.

Spine (Phila Pa 1976). 2003 May 1;28(9):851-8; discussion 859.

PMID:
12941996
17.

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.

Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.

Curr Med Res Opin. 2006 Jan;22(1):199-210.

PMID:
16393445
18.

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.

Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, Recker DP.

Rheumatology (Oxford). 2002 Sep;41(9):1008-16.

PMID:
12209034
19.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group.

Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800.

20.

Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain.

Reicin A, Brown J, Jove M, deAndrade JR, Bourne M, Krupa D, Walters D, Seidenberg B.

Am J Orthop (Belle Mead NJ). 2001 Jan;30(1):40-8.

PMID:
11198829

Supplemental Content

Support Center